Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF(V600E)-mutated melanoma Meeting Abstract
| Authors: | Hauschild, A.; Grob, J. J.; Demidov, L. V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C. U.; Mirakhur, B.; Guckert, M. E.; Swann, R. S.; Haney, P.; Martin, A. M.; Ouellet, D.; Grotzinger, K.; Goodman, V. L.; Chapman, P. B. |
| Abstract Title: | Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF(V600E)-mutated melanoma |
| Meeting Title: | 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2012 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-06-20 |
| Language: | English |
| ACCESSION: | WOS:000318026200033 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2012.30.18_suppl.lba8500 |
| Notes: | Meeting Abstract: LBA8500^ -- Source: Wos |
